Immunovant (IMVT) stock fell ~6% on Sept 23 after IMVT-1402 cutaneous lupus study missed primary endpoint; program discontinued. Law firm Levi & Korsinsky announces investigation into potential securities law violations. Stock hit more-than-three-month low.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
